Body of evidence grows for Cynata’s stem cell production platform

“Published” is an accolade that many scientists strive for. Showcasing your work and communicating your results to peers feels good, regardless of age. 

The setting of scientific show and tell is within scientific journals, offering an enduring record of a scientist’s findings and impact on the world (vastly less obtrusive than being sat down and made to watch your peers flaunt RC cars and the latest mermaid Barbie).

The clever crew at clinical stage biotechnology company Cynata (ASX: CYP) have made their mark, publishing a paper in Cytotherapy, the official journal of the International Society for Cell & Gene Therapy. 

The paper delves into preclinical study results showing the beneficial effects of stem cells from Cynata’s proprietary therapeutic stem cell platform technology, Cymerus, in heart attack models. 

Led by Associate Professor James Chong from the Westmead Institute for Medical Research in Sydney, the study revealed that Cymerus derived stem cells outperformed bone marrow derived stem cells in the treatment of heart attacks. Treatment with Cymerus stem cells resulted in enhanced cardiac function and increased arteriole and capillary generation without causing irregular heart rhythms. 

The study validates Cynata’s patented Cymerus platform and adds to the growing body of evidence in favour of the technology. 

A major challenge preventing widespread stem cell therapies are production methods. Cynata manages to circumvent the need for multiple stem cell donors to manufacture stem cell products at commercial scale through the use of precursor cells. 

Cymerus stem cell products are currently in Phase 3 trials for the treatment of osteoarthritis and respiratory failure. The Company is also investigating the use of Cymerus cells in patients with graft-versus-host-disease (transplant rejection), diabetic foot ulcers, critical limb ischaemia, idiopathic pulmonary fibrosis, and renal transplantation. In addition, Cynata has demonstrated their product’s efficacy via various preclinical studies in asthma, acute respiratory distress syndrome, cytokine release syndrome and now, heart attack. 

Dr. Kilian Kelly, CEO of Cynata, said: “We are pleased to see this paper being published in a leading peer-reviewed journal. The studies conducted by A/Prof Chong and his team have generated important insights into the potential utility of Cymerus MSCs in the treatment of heart attacks, as well as the mechanisms of action that lie behind these beneficial effects. This further strengthens the body of data that we have built up in support of the Cymerus platform over the last few years.” 

Management will be welcoming this news following a few months of downtrending share price.